MetLife (MET) Form 4: Director Carla Harris Reinvests Dividends for 30 Shares

Carla A. Harris, a director of MetLife, Inc. (MET), reported an internal share acquisition on 09/09/2025.

Rhea-AI Filing Summary

Carla A. Harris, a director of MetLife, Inc. (MET), reported an internal share acquisition on 09/09/2025. The Form 4 shows an imputed reinvestment of dividends under MetLife's Deferred Compensation Plan for Non-Management Directors, resulting in the acquisition of 30 shares at a reported price of $79.29 per share. After this transaction, Ms. Harris beneficially owns 8,514 shares in a direct capacity. The filing was signed by an attorney-in-fact on 09/11/2025.

Positive

• Director participation in deferred-compensation plan through dividend reinvestment, showing alignment with company equity
• Transparent disclosure of insider ownership and the small transaction, supporting SEC reporting requirements

Negative

• None.

Insights

Securities Analyst

TL;DR: Small dividend-reinvestment purchase by a director; signals routine alignment but is immaterial to valuation.

The reported A(1) transaction reflects an imputed reinvestment of dividends into 30 common shares at $79.29 each under the director deferred compensation plan. This is a mechanistic, non-market open-market purchase tied to dividend deferral rather than an independent buy decision. The post-transaction direct ownership of 8,514 shares is disclosed, which is useful for insider ownership tracking but is not large enough to alter control or materially affect investor views on MetLife's capital structure.

Corporate Governance Expert

TL;DR: Routine director dividend deferral; demonstrates participation in company plan but carries no governance change.

The Form 4 documents the mechanics of a deferred-compensation dividend reinvestment (imputed reinvestment), an administrative transaction common for non-management directors. There is no evidence of discretionary market purchases or sales, no change in director status, and no derivative activity. From a governance perspective this is standard disclosure that maintains transparency about director holdings.

Insider Trade Summary

Grant/Award: 30 shares

Grant/Award 1 txn

Insider Harris Carla A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	30	$79.29	$2K

Holdings After Transaction: Common Stock — 8,514 shares (Direct)

Footnotes (1)

1. F1. Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.

FAQ

What did MetLife director Carla A. Harris report on Form 4 (MET)?

The Form 4 reports an imputed reinvestment of dividends that acquired 30 shares at a reported price of $79.29 on 09/09/2025, leaving 8,514 shares beneficially owned directly.

Was the transaction an open-market purchase or part of a plan?

It was part of MetLife's Deferred Compensation Plan for Non-Management Directors, recorded as an imputed reinvestment of dividends, not an open-market trade.

Does this Form 4 show any derivative or option activity for Carla A. Harris?

No. Table II for derivative securities contains no reported transactions; only a non-derivative acquisition of common stock is reported.

When was the Form 4 signed and filed?

The filing shows the signature by an attorney-in-fact on 09/11/2025 reflecting the reported 09/09/2025 transaction date.

How material is this transaction to MetLife investors?

The acquisition of 30 shares is immaterial in size relative to MetLife's market capitalization and does not indicate a material change in insider ownership or control.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/11/2025 - 04:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Harris Carla A

(Last) (First) (Middle)

METLIFE, INC.

200 PARK AVENUE

(Street)

NEW YORK NY 10166

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
METLIFE INC [ MET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/09/2025		A(1)		30	A	$79.29	8,514	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.

Remarks:

	/s/ Taylor McInerney Jansen, Attorney-in-fact	09/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.